Crossmark

ASO Visual Abstract: CA19-9 Response to First-Line Neoadjuvant FOLFIRINOX and Second-Line Gemcitabine/ nab-Paclitaxel for Patients with Operable Pancreatic Cancer

Crossref DOI link: https://doi.org/10.1245/s10434-023-13160-9

Published Online: 2023-03-06

Published Print: 2023-05

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Thalji, Sam Z.

Kamgar, Mandana

George, Ben

Aldakkak, Mohammed

Christians, Kathleen K.

Clarke, Callisia N.

Erickson, Beth A.

Hall, William A.

Tolat, Parag P.

Smith, Zachary L.

Evans, Douglas B.

Tsai, Susan
License Information

Text and Data Mining valid from 2023-03-06

Version of Record valid from 2023-03-06
More Information

Article History

First Online: 6 March 2023

Disclosure

: There are no conflicts of interest.

Free to read: This content has been made available to all.

Document is current

Any future updates will be listed below